Pancreatic Cancer Research

ResearcherAsan Medical CenterActive in the last 2 years

Tae Won Kim

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-9522-1997; OpenAlex author ID A5101425291, A5126877597. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
29
Papers, trials and grants by year

2012: 3 papers · 2013: none · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 8

  1. Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 St… Co-author DOI 10.1158/2767-9764.crc-26-0018↗
  2. Chemosensitivity to HM90822, a novel synthetic IAP antagonist, is determined by p-AKT-inducible XIAP phosphorylation in human pancreatic cancer cells. Last author DOI 10.1007/s10637-020-00956-9↗
  3. Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing. Co-author DOI 10.1007/s10637-017-0497-1↗
  4. SAHA, an HDAC inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by modulating E-cadherin. Last author DOI 10.1007/s13277-015-4216-2↗
  5. A novel small-molecule IAP antagonist, AZD5582, draws Mcl-1 down-regulation for induction of apoptosis through targeting of cIAP1 and XIAP in human pancreatic … Last author DOI 10.18632/oncotarget.4822↗
  6. Radiofrequency ablation of liver metastasis in patients with locally controlled pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.jvir.2012.01.080↗
  7. YM155 induces EGFR suppression in pancreatic cancer cells. Last author DOI 10.1371/journal.pone.0038625↗
  8. The survivin suppressant YM155 potentiates chemosensitivity to gemcitabine in the human pancreatic cancer cell line MiaPaCa-2. Last author PMID 22593446↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ronnie Shapira‐Frommer · 1 shared paper, 2026 · strength 0.23
  2. Mariano Ponz‐Sarvisé · 1 shared paper, 2026 · strength 0.23
  3. Armando Santoro · 1 shared paper, 2026 · strength 0.23
  4. Giampaolo Tortora · 1 shared paper, 2026 · strength 0.23
  5. Jai-Hee Moon · 3 shared papers, 2015–2020 · strength 0.17
  6. Kyu‐pyo Kim · 3 shared papers, 2015–2018 · strength 0.15
  7. Jae‐Lyun Lee · 3 shared papers, 2012–2018 · strength 0.12
  8. Song Cheol Kim · 2 shared papers, 2012–2018 · strength 0.09
  9. Eun Kyung Choi · 2 shared papers, 2015–2016 · strength 0.08
  10. Seungwoo Hong · 1 shared paper, 2020 · strength 0.08
  11. Ki Byung Song · 1 shared paper, 2018 · strength 0.06
  12. Do Hyun Park · 1 shared paper, 2018 · strength 0.06
  13. Dae Wook Hwang · 1 shared paper, 2018 · strength 0.06
  14. Sang Hyun Shin · 1 shared paper, 2018 · strength 0.06
  15. Tae Jun Song · 1 shared paper, 2018 · strength 0.06
  16. Kyoungmin Lee · 1 shared paper, 2018 · strength 0.06
  17. Myung‐Hwan Kim · 1 shared paper, 2018 · strength 0.06
  18. W. Lee · 1 shared paper, 2018 · strength 0.06
  19. Dong Wan Seo · 1 shared paper, 2018 · strength 0.06
  20. Baek‐Yeol Ryoo · 1 shared paper, 2018 · strength 0.06
  21. Changhoon Yoo · 1 shared paper, 2018 · strength 0.06
  22. Sang Soo Lee · 1 shared paper, 2018 · strength 0.06
  23. Dok Hyun Yoon · 2 shared papers, 2012 · strength 0.06
  24. Seongjoon Park · 1 shared paper, 2016 · strength 0.05
  25. Young Hoon Kim · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.